Mind Medicine (MindMed) Inc. Common Shares (MNMD) Dividend History

Company News

• Why Mind Medicine Stock Is Skyrocketing Today

  Mind Medicine's stock is surging after Robert F. Kennedy Jr. was confirmed as the new U.S. Health and Human Services secretary. Kennedy has previously voiced support for psychedelics as therapeutic treatments, which could benefit Mind Medicine's drug development efforts.

  The Motley Fool
• 5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

  The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.

  GlobeNewswire Inc.

  Featured Companies: ATAI CYBN HRMY RVPH
• Why Mind Medicine Stock Is Soaring Today

  A Minnesota task force has urged the decriminalization of psilocybin mushrooms and supported greater funding for psychedelics research. This could benefit MindMed, a clinical-stage biotech company focused on potential medical applications for psychedelics.

  The Motley Fool
• 4 Psychedelic Stocks to Consider as Clinical Trials Heat up

  Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.

  Investing.com

  Featured Companies: ATAI
• Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?

  Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

  Zacks Investment Research

  Featured Companies: RMD